| Intrinsic Valuation of: BIOCON | |||||||||||
| Free Cash Flow Average and Growth over past 5Y | Key Statistics | ||||||||||
| Year | FCF | FCF (FCF/Revenue) | |||||||||
| 2020 | - | - | EPS (FY) | 8 | Market Cap | ₹484B | |||||
| 2021 | - | - (-) | P/E Ratio | 43 | Total Asset | ₹588B | |||||
| 2022 | ₹-7B | - (-) | Net Income | ₹10B | Total Debt | ₹124B | |||||
| 2023 | ₹1B | 116.9% (112.4%) | EBITDA | ₹45B | Total Liab | ₹311B | |||||
| 2024 | ₹10B | 710.1% (523.9%) | Opr Margin | 0.09 | Debt/Equity | 0.45 | |||||
| 2025 | ₹17B | 68.0% (58.5%) | PreTax Margin | 2.89 | BV/Share | -41 | |||||
| 5Y Average FCF | ₹5B | 298.3% (231.6%) | |||||||||
| Overall Market Assumptions: | |||||||||||
| Assumptions: | P/E for No-Growth Company: | 7.0 | |||||||||
| Perpetual Growth Rate (g): | 2.5% | Historical US Bond Yield: | 4.4% | ||||||||
| Discount Rate (WACC): | 7.4% | Current US Bond Yield: | 3.5% | ||||||||
| Forcasting Future Free Cash Flow for next 6Y | Modified Benjamin Graham's Intrinsic Value | ||||||||||
| Year | FCF Projection (25.0%) | ||||||||||
| 2026 | ₹21B | MBG Intrinsic Value | ₹76 | ||||||||
| 2027 | ₹27B | ||||||||||
| 2028 | ₹34B | ||||||||||
| 2029 | ₹42B | ||||||||||
| 2030 | ₹52B | ||||||||||
| 2031 | ₹66B | ||||||||||
| Terminal Value | ₹1,362B | Net Worth/Share | ₹208 | ||||||||
| DCF Valuation | DCF Valuation "What If" Scenario Table | ||||||||||
| Enterprise Value | ₹1,067B | Growth Rate | |||||||||
| (+) Cash & Cash Equivalents | ₹32B | ₹731 | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% | ||||
| (-) Total Debt | ₹124B | WACC | 7.3% | 627 | 682 | 749 | 831 | 935 | |||
| Equity Value | ₹976B | 7.4% | 620 | 674 | 740 | 820 | 922 | ||||
| Shares Outstanding | 1,334,550,016 | 7.4% | 614 | 667 | 731 | 810 | 908 | ||||
| 7.9% | 555 | 599 | 651 | 713 | 790 | ||||||
| DCF Intrinsic Value | ₹731 | 8.4% | 505 | 541 | 584 | 635 | 696 | ||||
| Analyzed by QuantJuice (2025) | |||||||||||